MEDICAID POLICY INFORMATION SHEET

Policy Analyst: Rajita Dnyate

Phone Number: 517	7-284-1204		
Initial	Public Comment	Final 🖂	

Brief description of policy:

COVID-19 vaccines will soon be made available as per the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommendations. COVID-19 vaccine products are being procured and purchased by the federal government; therefore, it will be made available to Medicaid providers at no cost. This policy provides auidance to Medicaid enrolled providers about coverage and reimbursement of COVID-19 vaccines.

Reason for policy (problem being addressed):

To inform all Medicaid providers about COVID-19 vaccine services.

Budget implication:

budget neutral	
will cost MDHHS	\$ 48.1 million total (\$8.9 million general fund), and is not budgeted in
current appropriation	
will save MDHHS	\$

Is this policy change mandated per federal requirements?

No.

Does policy have operational implications on other parts of MDHHS?

No

Does policy have operational implications on other departments?

No

Summary of input:

controversial

 \boxtimes acceptable to most/all groups

limited public interest/comment

Supporting Documentation:

State Plan Amendment Re	uired: 🛛 Yes 🛛 🗌 No	Public Notice Required:	🛛 Yes	🗌 No
If Yes, please provide state	5:			
Approved Sendi	g 🗌 Denied	If yes,		
Date: Approval	Date:	Submission Date:		

DRAFT FOR PUBLIC COMMENT		
Michigan Department of		
Health and Human Services	Project Number: 2073-Vaccine	Date: December 23, 2020
Comments Due: Janu Proposed Effective Date: As lu Direct Comments To: Rajit Address: E-Mail Address: dnya	a Dnyate	
Phone: 517-	284-1204 F	ax:
Policy Subject: COVID-19 Rest	oonse: Coverage of COVID-19 Vac	ccine Services
Affected Programs: Medicaid, Healthy Michigan Plan, MIChild, Maternity Outpatient Medical Services (MOMS), Emergency Services Only (ESO), MI Health Link		
Distribution: All Providers		
Summary: COVID-19 vaccines will soon be made available as per the Centers for Disease Control and Prevension (CDC) Advisory Committee on Immunization Practices (ACIP) recommendations. COVID-19 vaccine products are being procured and purchased by the federal government; therefore, it will be made available to Medicaid providers at no cost. This policy provides guidance to Medicaid enrolled providers about coverage and reimbursement of COVID-19 vaccines.		
Purpose: To inform all Medicaid	providers about COVID-19 vaccine	e services.
Cost Implications: \$48.1 million appropriation.	total (\$8.9 million general fund) and	d is not budgeted in current
Potential Hearings & Appeal Issues: None		
State Plan Amendment Required: Yes INO Public Notice Required: Yes INO If yes, date submitted: Submitted date:		
Tribal Notification: Yes 🖂 No 🗌 - Date:		
THIS SECTION COMPLETED BY RECEIVER		
Approved	No Commen	ts
	See Commer	
Disapproved	See Commer	nts in Text
Signature:	Phone Nu	mber

Signature Printed:		
Bureau/Administration (please print)	Date	
Comment001	F	Revised 6/16



Bulletin Number:	MSA 20-75
Distribution:	All Providers
Issued:	December 23, 2020
Subject:	COVID-19 Response: Coverage of COVID-19 Vaccine Services
Effective:	As Indicated
Programs Affected:	Medicaid, Healthy Michigan Plan, MIChild, Maternity Outpatient Medical Services (MOMS), Emergency Services Only (ESO), MI Health Link

Medical Services Administration

Note: Implementation of this policy is contingent upon approval of a State Plan Amendment (SPA) by the Center for Medicare & Medicaid Services (CMS).

This bulletin notifies Michigan Department of Health and Human Services (MDHHS) Medicaid enrolled providers of important information regarding the Medicaid program coverage of the COVID-19 vaccine effective for dates of service on or after December 1, 2020. The bulletin includes the following:

- Medicaid Coverage and Reimbursement of COVID-19 Vaccines
- New Common Procedural Terminology (CPT®) Codes
- MDHHS COVID-19 Vaccination Plan Information, Provider Registration and Resources

Medicaid Health Plans (MHPs) and Integrated Care Organizations (ICOs) must ensure that enrollees have full freedom of choice of COVID-19 vaccine providers, both in-network and out-of-network. Additionally, MHPs and ICOs must pay out-of-network providers at established Medicaid Fee for Service (FFS) rates in effect on the date of service for COVID-19 vaccine administration services.

Medicaid Coverage and Reimbursement of COVID-19 Vaccines

COVID-19 Vaccine Product Coverage

COVID-19 vaccine products will be covered when given according to the recommendations of the Center for Disease Control (CDC)'s Advisory Committee on Immunization Practices (ACIP).

During the PHE, COVID-19 vaccine products are being procured and purchased by the federal government; therefore, it will be made available to Medicaid providers at no cost. Medicaid will not reimburse providers for federally purchased or free vaccine products. Providers must bill the procedure code and the cost of the vaccine as \$0.00.

Following the PHE, Food & Drug Administration (FDA) approved COVID-19 vaccines will be covered and reimbursed consistent with existing Medicaid policies.

COVID-19 Vaccine Administration Coverage

Coverage for the administration services of the COVID-19 vaccine will be similar to existing vaccine administration services billed to Medicaid. Please refer to Section 3.12 in the Practitioner Chapter and Section 6.4 of the Billing and Reimbursement for Professionals Chapter of the Medicaid Provider Manual for detailed information regarding billing and reimbursement for vaccine administration. The Medicaid Provider Manual can be found on the MDHHS website at www.michigan.gov/medicaidproviders >> Policy, Letters and Forms.

Reimbursement for COVID-19 vaccine administration services will be at 100% of Medicare rates for equivalent services. All reimbursement rates will be reviewed and updated as applicable and are published on the MDHHS website at www.michigan.gov/medicaidproviders >> Billing & Reimbursement >> Provider Specific Information.

Cost Sharing Exemption

COVID-19 vaccine services will be covered without co-payment. Beneficiaries will not incur, and providers should not collect, co-pays for COVID-19 vaccine services.

Emergency Services Only (ESO)

COVID-19 vaccine services will be covered for beneficiaries with the ESO benefit plan. Services will be covered consistent with treatment provisions outlined in MSA 20-24.

Federally Qualified Health Centers (FQHCs), Rural Health Clinics (RHCs), Tribal Health Centers (THCs) and Tribal FQHC Reimbursement for COVID-19 Vaccine Administration

FQHCs, RHCs, THCs and Tribal FQHCs may be reimbursed for COVID-19 vaccine administration when no other eligible qualifying clinic visit is provided on the same date of service. COVID-19 administration fees will be excluded from the prospective payment system methodology and all-inclusive rate methodology and reimbursed at a fee screen pursuant to the practitioner payment methodology as described above. All identifiable financial resources must be utilized for COVID-19 vaccine administration services provided to Medicaid beneficiaries prior to the use of Medicaid funds. A provider will not be eligible for Medicaid reimbursement if COVID-19 vaccine administration services were provided under another Federal or State of Michigan program or contract.

Pharmacy Billing and Reimbursement

Pharmacies may bill and will be reimbursed for the COVID-19 vaccine administration in accordance with existing policies and reimbursement rates that align with the practitioner fee screens as described above. Any pharmacy specific COVID-19 vaccine services billing instructions will be published on the pharmacy website at:

<u>https://michigan.magellanrx.com/provider/</u> and also incorporated into the Pharmacy Claims Processing Manual at: <u>https://michigan.magellanrx.com/provider</u> >> Documents >> Manuals.

New COVID-19 Vaccine Related Procedure Codes

MDHHS will be covering new CPT codes for reporting COVID-19 vaccine services. The coding information provided below is based on the most recent information from CMS and American Medical Association (AMA). It is anticipated that coverage of any future COVID-19 vaccine CPT reporting codes will be available for use and effective upon each new coronavirus vaccine receiving approval from the FDA.

Providers are highly encouraged to review the latest CPT coding guidance on the new reporting structure and additional resources available for COVID-19 vaccine and immunization services provided by the AMA at: <u>https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes</u>.

Vaccine Product Codes

<u>Pfizer</u>

91300 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use

<u>Moderna</u>

91301- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use

Vaccine Administration Codes

<u>Pfizer</u>

0001A – Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose

0002A - Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose

<u>Moderna</u>

0011A - Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose

0012A - Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose

Information regarding fee screens is maintained on the appropriate database or professional fee schedule on the MDHHS website at <u>www.michigan.gov/medicaidproviders</u> >> Billing and Reimbursement >> Provider Specific Information. Additional pertinent coverage parameters are accessible via the Medicaid Code and Rate Reference tool within CHAMPS.

MDHHS COVID-19 Vaccination Program Information, Provider Registration, and Resources

In response to the COVID-19 PHE, MDHHS has developed a statewide COVID-19 Vaccination Program to distribute vaccines as they become available. In accordance with that plan, Medicaid enrolled providers seeking reimbursement for COVID-19 vaccine administration services must be registered with the MDHHS Division of Immunization's COVID-19 Vaccination Program. Links to provider registration and the online applications can be found at https://www.michigan.gov/coronavirus/0,9753,7-406-98178_98156---,00.html.

Enrolled COVID-19 vaccination providers must be in adherence to both the conditions in the CDC COVID-19 Vaccination Program Provider Agreement and the Department's rules and regulations for vaccine administration.

Pharmacies currently participating at the Federal level (federal pharmacy contract to vaccinate Long Term Care/Skilled Nursing Facilities) SHOULD NOT apply at the Michigan level. However, these pharmacies need to be registered in Michigan Care Improvement Registry (MCIR). Link to MCIR provider registration can be found at-<u>https://www.mcir.org/registration/.</u>

Once MDHHS COVID-19 Provider Registration has been approved, the approved site will begin receiving "next steps" information emails. Questions on registration should be directed to: <u>MDHHS-COVIDVaccineProviders@michigan.gov</u>

Information on the MDHHS COVID-19 Vaccination Program can be found at:

- <u>www.michigan.gov/coronavirus</u> >>Resources>>COVID-19 Vaccine
- <u>www.michigan.gov/coronavirus</u> >>Resources >>For Health Professionals

Additional COVID-19 Vaccine Resources

CDC: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html

Public Comment

The public comment portion of the policy promulgation process is being conducted concurrently with the implementation of the change noted in this bulletin. Any interested party wishing to comment on the change may do so by submitting comments to Rajita Dnyate via e-mail at <u>DnyateR@michigan.gov</u>.

Please include "COVID-19 Response: Coverage of COVID-19 Vaccine Services" in the subject line.

Comments received will be considered for revisions to the change implemented by this bulletin.

Manual Maintenance

Information is time-limited and will not be incorporated into any policy or procedure manuals.

Questions

Any questions regarding this bulletin should be directed to Provider Inquiry, Department of Health and Human Services, P.O. Box 30731, Lansing, Michigan 48909-8231, or e-mailed to <u>ProviderSupport@michigan.gov</u>. When you submit questions, be sure to include your name, affiliation, NPI number, and phone number so you may be contacted if necessary. Providers may phone toll-free 800-292-2550.

Approved

Kate Massey, Director Medical Services Administration